Citations

Showing 10 of 108104 citations.

Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
Symonds, Lynn , Carter, Kelly , Innocenti, Federico , Bosch, Linda J.W. , Meijer, Gerrit A , Carvalho, Beatriz , Zemla, Tyler J, Carter, Kelly , Meijer, Gerrit A , Yu, Ming , Zhang, Yuhong , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Grady, William M. , Cohen, Stacey A.

Mayo Clinic

Epigenetics | April 12, 2022 | Volume: 17 | Issue: 12 | Pages: 1715-1725

10.1080/15592294.2022.2058225 | PMID 35412430 Get It

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Prawira, Amy , Antonia, Scott , Rahma, Osama E. , Cohen, Roger B. , Lou, Yanyan , Hauke, Ralph J. , Zandberg, Dan P. , Kalebasty, Arash Rezazadeh, Atkinson, Victoria , Adjei, Alex A. , Seetharam, ­Mahesh , Birnbaum, Ariel E., Weickhardt, Andrew , Ganju, Vinod , Cavallo, Rosetta, Zhang, Xiaoyu , Kaul, Sanjeev, Baughman, Jan, Bonvini, Ezio , Moore, Paul A. , Goldberg, S., Arnaldez, Fernanda I. , Aggarwal, Charu , Tolcher, Anthony W. , Vogelzang, Nicholas J. , Joshua, Anthony M. , Peng, Linda , Kaul, Sanjeev, Ferris, Robert L. , Lakhani, Nehal J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 12, 2022 | Volume: 10 | Issue: 4 | Pages: e004424

10.1136/jitc-2021-004424 | PMID 35414591 Get It

Background Availability of checkpoint inhibitors has created a paradigm shift in the management of patients with solid tumors. Despite this, most patients do not respond to immunotherapy, and there is considerable interest in developing combination therapies to improve response rates and outcomes. B7-H3 (CD276) is a member of the B7 family of cell surface molecules and provides an alternative immune checkpoint molecule to therapeutically target alone or in combination with programmed cell death-1 (PD-1)–targeted therapies. Enoblituzumab, an investigational anti-B7-H3 humanized monoclonal antibody, incorporates an immunoglobulin G1 fragment crystallizable (Fc) domain that enhances Fcγ receptor-mediated antibody-dependent cellular cytotoxicity. Coordinated engagement of innate and adaptive immunity by targeting distinct members of the B7 family (B7-H3 and PD-1) is hypothesized to provide greater antitumor activity than either agent alone. Methods In this phase I/II study, patients received intravenous enoblituzumab (3–15 mg/kg) weekly plus intravenous pembrolizumab (2 mg/kg) every 3 weeks during dose-escalation and cohort expansion. Expansion cohorts included non–small cell lung cancer (NSCLC; checkpoint inhibitor [CPI]–naïve and post-CPI, programmed death-ligand 1 [PD-L1] <1%), head and neck squamous cell carcinoma (HNSCC; CPI-naïve), urothelial cancer (post-CPI), and melanoma (post-CPI). Disease was assessed using Response Evaluation Criteria in Solid Tumors version 1.1 after 6 weeks and every 9 weeks thereafter. Safety and pharmacokinetic data were provided for all enrolled patients; efficacy data focused on HNSCC and NSCLC cohorts. Results Overall, 133 patients were enrolled and received ≥1 dose of study treatment. The maximum tolerated dose of enoblituzumab with pembrolizumab at 2 mg/kg was not reached. Intravenous enoblituzumab (15 mg/kg) every 3 weeks plus pembrolizumab (2 mg/kg) every 3 weeks was recommended for phase II evaluation. Treatment-related adverse events occurred in 116 patients (87.2%) and were grade ≥3 in 28.6%. One treatment-related death occurred (pneumonitis). Objective responses occurred in 6 of 18 (33.3% [95% CI 13.3 to 59.0]) patients with CPI-naïve HNSCC and in 5 of 14 (35.7% [95% CI 12.8 to 64.9]) patients with CPI-naïve NSCLC. Conclusions Checkpoint targeting with enoblituzumab and pembrolizumab demonstrated acceptable safety and antitumor activity in patients with CPI-naïve HNSCC and NSCLC. Trial registration number NCT02475213.
Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis
Paraskevas, Kosmas I. , Mikhailidis, Dimitri P. , Ascher, Enrico, Baradaran, Hediyeh , Bokkers, Reinoud P.H. , Cambria, Richard P., Comerota, Anthony J. , Dardik, Alan , Davies, Alun H. , Faggioli, Gianluca , Fraedrich, Gustav , Geroulakos, George , Gloviczki, Péter , Golledge, Jonathan , Gupta, Ajay , Ježovnik, Mateja K. , Kakkos, Stavros K. , Katsiki, Niki , Knoflach, Michael , Kooi, M. Eline , Lavenson, George S., Loftus, Ian , Millon, Antoine , Poredoš, Pavel , Proczka, Robert M. , Riles, Thomas S., Saba, Luca , Schlachetzki, Felix , Silvestrini, Mauro , Spinelli, Francesco , Stilo, Francesco , Suri, Jasjit S. , Zeebregts, Clark J. , Jezovnik, Mateja K , Katsiki, Niki , Pini, Rodolfo , Poredos, Pavel , Svetlikov, Alexei V , Paraskevas, Kosmas I , Davies, Alun H , Kooi, Marianne Eline , Antignani, Pier Luigi , Eckstein, Hans‐Henning , Fernandes, José Fernandes e , Lanza, Gaetano A , Liapis, Christos D. , Mansilha, Armando , Nicolaides, Andrew , Ricco, Jean‐Baptiste , Ringleb, Peter Arthur , Rundek, Tatjana , Saba, Luca , Sultan, Sherif A. H. , Suri, Jasjit S. , Chaturvedi, Seemant , Gloviczki, Péter

Mayo Clinic

Angiology | April 12, 2022 | Volume: 73 | Issue: 10 | Pages: 903-910

10.1177/00033197221081914 | PMID 35412377 Get It

Despite the publication of several national/international guidelines, the optimal management of patients with asymptomatic carotid stenosis (AsxCS) remains controversial. This article compares 3 recently released guidelines (the 2020 German–Austrian, the 2021 European Stroke Organization [ESO], and the 2021 Society for Vascular Surgery [SVS] guidelines) vs the 2017 European Society for Vascular Surgery (ESVS) guidelines regarding the optimal management of AsxCS patients. The 2017 ESVS guidelines defined specific imaging/clinical parameters that may identify patient subgroups at high future stroke risk and recommended that carotid endarterectomy (CEA) should or carotid artery stenting (CAS) may be considered for these individuals. The 2020 German–Austrian guidelines provided similar recommendations with the 2017 ESVS Guidelines. The 2021 ESO Guidelines also recommended CEA for AsxCS patients at high risk for stroke on best medical treatment (BMT), but recommended against routine use of CAS in these patients. Finally, the SVS guidelines provided a strong recommendation for CEA+BMT vs BMT alone for low-surgical risk patients with >70% AsxCS. Thus, the ESVS, German–Austrian, and ESO guidelines concurred that all AsxCS patients should receive risk factor modification and BMT, but CEA should or CAS may also be considered for certain AsxCS patient subgroups at high risk for future ipsilateral ischemic stroke.
Application of the advanced lung cancer inflammation index for patients with coronavirus disease 2019 pneumonia: Combined risk prediction model with lung cancer inflammation index, computed tomography and chest radiograph
Takahashi, Hiroaki , Ibe, Tatsuya, Ishii, Hisashi, Kurata, Yuhei, Ishizuka, Yoshikazu, Batsaikhan, Bolorkhand, Hamamoto, Yoichiro , Inoue, Akitoshi , Takahashi, Hiroaki , Ishii, Hisashi, Ishizuka, Yoshikazu

Mayo Clinic

Experimental and Therapeutic Medicine | April 12, 2022 | Volume: 23 | Issue: 6 | Pages: No page available

10.3892/etm.2022.11315 | PMID 35495600 Get It

Rasch‐calibrated Intermittent Exotropia Symptom Questionnaire for Children
Holmes, Jonathan M., Leske, David A., Hercinovic, Amra, Hatt, Sarah R., Chandler, Danielle L., Li, Zhuokai, Melia, B. Michele, Chen, Angela M., Erzurum, Sergul Ayse, Crouch, Eric R., Jenewein, Erin C., Kraker, Raymond T., Cotter, Susan A., Group, Pediatric Eye Disease Investigator, Holmes, Jonathan M. , Holmes, Jonathan M., Leske, David A., Hercinovic, Amra, Hatt, Sarah R., Chandler, Danielle L., Li, Zhuokai, Melia, B. Michele, Chen, Angela M., Erzurum, Sergul Ayse, Crouch, Eric R., Jenewein, Erin C., Kraker, Raymond T., Cotter, Susan A., Group, Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Mayo Clinic

Optometry and Vision Science | April 12, 2022 | Volume: 99 | Issue: 6 | Pages: 513-520

10.1097/opx.0000000000001901 | PMID 35412528 Get It

SIGNIFICANCE A rigorously designed and calibrated symptom questionnaire for childhood intermittent exotropia would be useful for clinical care and for research. PURPOSE The aim of this study was to Rasch‐calibrate and evaluate the previously developed Child Intermittent Exotropia Symptom Questionnaire using data gathered as part of a randomized clinical trial. METHODS The questionnaire was administered to 386 children aged 3 to 10 years with intermittent exotropia who were enrolled in a randomized clinical trial comparing overminus with nonoverminus spectacles. Participants were followed at 6 and 12 months while on treatment and at 18 months off treatment. Factor analysis determined dimensionality, and Rasch analysis evaluated questionnaire performance. Logit values were converted to 0 (best) to 100 (worst). We evaluated differences in questionnaire scores between treatment groups and time points, and correlations with control scores. RESULTS The Child Intermittent Exotropia Symptom Questionnaire was unidimensional. Rasch analysis indicated that there was no notable local dependence and no significant differential item functioning for sex or age. There was suboptimal targeting (mean logit, −1.62), and person separation was somewhat poor (0.95). There were no significant differences in the Child Intermittent Exotropia Symptom score between overminus spectacles and nonoverminus spectacles at 6, 12, and 18 months. Combining data from both treatment groups, there was significant improvement from baseline at all follow‐up visits (e.g., mean change from baseline to 12 months, −6.6 points; 95% confidence interval, −8.6 to −4.6). Child Intermittent Exotropia Symptom scores were not correlated with distance or near control scores at 12 months. CONCLUSIONS The seven‐item Rasch‐scored Child Intermittent Exotropia Symptom Questionnaire is limited by suboptimal performance. Future study is needed to determine whether it may be useful for clinical practice and for research.
Establishing a National Cardiovascular Disease Surveillance System in the United States Using Electronic Health Record Data: Key Strengths and Limitations
Williams, Brent A. , Voyce, Stephen , Sidney, Stephen , Roger, Véronique L. , Plante, Timothy B. , Larson, Sharon , LaMonte, Michael J. , Labarthe, Darwin R. , DeBarmore, Bailey M. , Chang, Alex R. , Chamberlain, Alanna M. , Benziger, Catherine P. , Chamberlain, Alanna M , Benziger, Catherine P , Chang, Alexander R

Mayo Clinic

Journal of the American Heart Association | April 12, 2022 | Volume: 11 | Issue: 8 | Pages: No page available

10.1161/jaha.121.024409 | PMID 35411783 Get It

Cardiovascular disease surveillance involves quantifying the evolving population‐level burden of cardiovascular outcomes and risk factors as a data‐driven initial step followed by the implementation of interventional strategies designed to alleviate this burden in the target population. Despite widespread acknowledgement of its potential value, a national surveillance system dedicated specifically to cardiovascular disease does not currently exist in the United States. Routinely collected health care data such as from electronic health records (EHRs) are a possible means of achieving national surveillance. Accordingly, this article elaborates on some key strengths and limitations of using EHR data for establishing a national cardiovascular disease surveillance system. Key strengths discussed include the: (1) ubiquity of EHRs and consequent ability to create a more “national” surveillance system, (2) existence of a common data infrastructure underlying the health care enterprise with respect to data domains and the nomenclature by which these data are expressed, (3) longitudinal length and detail that define EHR data when individuals repeatedly patronize a health care organization, and (4) breadth of outcomes capable of being surveilled with EHRs. Key limitations discussed include the: (1) incomplete ascertainment of health information related to health care–seeking behavior and the disconnect of health care data generated at separate health care organizations, (2) suspect data quality resulting from the default information‐gathering processes within the clinical enterprise, (3) questionable ability to surveil patients through EHRs in the absence of documented interactions, and (4) the challenge in interpreting temporal trends in health metrics, which can be obscured by changing clinical and administrative processes.
Prevalence and Outcomes of Bicuspid Aortic Valve in Patients With Aneurysmal Sub‐Arachnoid Hemorrhage: A Prospective Neurology Registry Report
Vallabhajosyula, Saarwaani , Thomas, Sarah , Maleszewski, Joseph J. , Boler, Amber, Thapa, Prabin , Enriquez‐Sarano, Maurice , Rabinstein, Alejandro A. , Michelena, Héctor I. , Yang, Li-Tan, Thomas, Sarah C, Maleszewski, Joseph J , Enriquez-Sarano, Maurice , Rabinstein, Alejandro A , Michelena, Hector I , Yang, Li‐Tan , Thomas, Sarah C.

Mayo Clinic

Journal of the American Heart Association | April 12, 2022 | Volume: 11 | Issue: 8 | Pages: No page available

10.1161/jaha.121.022339 | PMID 35411791 Get It

Background Intracranial aneurysms are reported in 6%–10% of patients with bicuspid aortic valve (BAV), and routine intracranial aneurysm surveillance has been advocated by some. We assessed the prevalence and features of the most important patient‐outcome: aneurysmal sub‐arachnoid hemorrhage (aSAH), as compared with controls without aSAH, and tricuspid aortic valve (TAV) with aSAH. Methods and Results Adult patients with accurate diagnosis of aSAH and at least one echocardiogram between 2000 and 2019 were identified from a consecutive prospectively maintained registry of aSAH admissions. Controls without a diagnosis of SAH were age‐ and sex‐matched. BAV prevalence was confirmed echocardiographically. Severity of aSAH was categorized using modified Fisher and World Federation of Neurological Scale. Neurologic outcome was assessed using modified Rankin score. A total 488 aSAH cases and 990 controls were identified and BAV status was confirmed. Prevalence of BAV in patients with aSAH was 1.2% (6/488) versus 3.5% (35/990) in controls, P =0.01. BAV+aSAH were noted to be younger than TAV+aSAH (56±11 versus 68±14; P =0.03) with smaller aneurysms (5±2 versus 7±4; P =0.31). The severity of aSAH was lesser in BAV+aSAH than TAV (modified Fisher grade>2 50% versus 74%; P =0.19, World Federation of Neurological Scale grade>3 17% versus 36%; P =0.43). BAV+aSAH had less severe neurologic disability (modified Rankin score 3%–6 33% versus 49% in TAV; P =0.44) and comparable in‐hospital mortality rates ( P =0.93). BAV had lower odds for aSAH on multivariate analysis (odds ratio 0.23[CI 0.08–0.65]; P =0.01). Conclusions Prevalence of BAV was 3 times lower in the aSAH registry than in controls without aSAH. BAV+aSAH had clinically smaller aneurysms, clinically smaller bleeds, and better neurologic outcome as compared with TAV+aSAH, which needs to be confirmed in larger studies. These findings argue against routine surveillance for intracranial aneurysms in patients with BAV without aortic coarctation.
Effect of liquid and solid test meals on symptoms and gastric myoelectrical activity in patients with gastroparesis and functional dyspepsia
Koch, Kenneth L. , Natta, Mark L. Van , Parkman, Henry P. , Grover, Madhusudan , Abell, Thomas L. , McCallum, Richard W. , Shaltout, Hossam A. , Sarosiek, Irene , Farrugia, Gianrico , Shulman, Robert J. , Tonascia, James , Miriel, Laura , Hamilton, Frank A., Pasricha, Pankaj J. , Parkman, H P , Abell, T L

Mayo Clinic

Neurogastroenterology & Motility | April 12, 2022 | Volume: 35 | Issue: 2 | Pages: No page available

10.1111/nmo.14376 | PMID 35411675 Get It

AbstractBackgroundPatients with gastroparesis (GP) and functional dyspepsia (FD) have similar symptoms, but the pathophysiology of postprandial symptoms remains uncertain.AimsTo compare symptoms and gastric myoelectrical activity (GMA) after liquid and solid test meals in patients with GP and FD.MethodsPatients enrolled in the Gastroparesis Clinical Research Consortium Registry were studied. Clinical characteristics were measured with standard questionnaires. GP was determined by 4‐h solid‐phase gastric scintigraphy. GMA was measured using electrogastrography before and after ingestion of a water load or nutrient bar on separate days. Symptoms were measured on visual analog scales. GMA responses to the water load for individual patients were also determined.Results284 patients with GP and 113 with FD were identified who ingested both test meals. Patients with GP and FD had similar maximal tolerated volumes of water [mean (SD) 378 (218) ml vs. 402 (226) ml,p = 0.23] and reported similar intensity of fullness, nausea, bloating, and abdominal discomfort after the test meals. Twenty‐six percent and 19% of the patients with GP and FD, respectively, ingested subthreshold (<238 ml) volumes of water (p = 0.15). Gastric dysrhythmias were recorded in 66% of the GP and 65% of the FD patients after the water load. Symptoms and GMA were similar in both groups after ingestion of the nutrient bar.ConclusionThe similarity in GMA responses and symptoms after ingestion of solid or liquid test meals suggests GP and FD are closely related gastric neuromuscular disorders.
Progress and Recent Advances in Solid Organ Transplantation
Kaewput, Wisit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Kaewput, Wisit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | April 12, 2022 | Volume: 11 | Issue: 8 | Pages: 2112

10.3390/jcm11082112 | PMID 35456205 Get It

Over the past decade, the number of organ transplants performed worldwide has significantly increased for patients with advanced organ failure [...]
Continuous Monitoring Detected Respiratory Depressive Episodes in Proximity to Adverse Respiratory Events During the PRODIGY Trial
Kor, Jennifer J., Šprung, Juraj , Khanna, Ashish K. , Weingarten, Toby N.

Mayo Clinic

Journal of Patient Safety | April 11, 2022 | Volume: 18 | Issue: 8 | Pages: 738-741

10.1097/pts.0000000000001003 | PMID 35405725 Get It

Purpose The PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial was a multicenter prospective trial conducted to develop a risk prediction score for opioid-induced respiratory depressive (OIRD) episodes. Several subjects in the PRODIGY trial developed critical respiratory depressive events, which were qualified as reportable adverse events (AEs). In this study, we determine whether those patients also had an episode of OIRD as detected by continuous capnography and pulse oximetry leading up to the critical clinical event. Methods Blinded capnography and pulse oximetry data from PRODIGY patients who had critical respiratory depressive AE were reviewed. The occurrence and timing of OIRD episodes were recorded in relationship to the AE. Results Of the 1335 subjects in PRODIGY, 7 patients had 8 reportable pulmonary AE and 187 OIRDs (150 apnea episodes, 14 bradypnea episodes, 23 hypoxic episodes) with median 12 (5–19.5) OIRDs per patient. Five patients were monitored before the AE, and multiple preceding OIRD episodes were detected. One patient had 2 AE, the first (hypoxemia) was recognized upon application of pulse oximetry. This patient subsequently had multiple OIRDs until the second AE occurred (somnolence requiring naloxone administration). Another patient’s AE (hypotension and bradypnea) was recognized upon monitor application and subsequently had many OIRD episodes. Conclusions In the PRODIGY trial, patients who had a pulmonary AE had multiple preceding OIRDs detected by continuous capnography and pulse oximetry. When monitoring was initiated before the AE, numerous OIRDs, mostly apneic episodes preceded AE, suggesting continuous monitoring of both ventilation and oxygenation may allow for early detection and possible prediction of future clinical decompensation.